Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 22.06.2026 1 ACS Nano 1 Am J Surg Pathol 1 Ann Surg Oncol 1 Anticancer Agents Med Chem 1 Arch Esp Urol 1 Arkh Patol 1 Asian J Endosc Surg 1 Biosens Bioelectron 2 BMC Cancer 1 Cancer Lett 1 Cell Chem Biol 1 Cell Death Discov 1 Cell Mol Biol Lett 1 Clin Chim Acta 1 Clin Exp Med 1 Clin Transl Oncol 2 Discov Oncol 1 Drug Resist Updat 2 Eur Urol 1 Exp Mol Pathol 1 Fr J Urol 1 Front Immunol 1 Front Nutr 3 Front Oncol 1 Hum Immunol 1 Immunol Res 1 Int J Nanomedicine 1 Int J Urol 1 Intern Med 1 J Am Vet Med Assoc 1 J Endourol 1 J Med Internet Res 1 J Nanobiotechnology 1 J Natl Compr Canc Netw 1 J Registry Manag 1 Mil Med Res 1 Mod Pathol 1 Mol Biol Rep 1 Mol Genet Genomics 1 Mol Oncol 2 N Engl J Med 1 Nat Cell Biol 1 Photodiagnosis Photodyn Ther 1 Rev Assoc Med Bras (1992) 1 Sci Rep 5 Transl Androl Urol 5 Urol Oncol 1 Urology 1 Virchows Arch 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Nano

1. GAO S, Zhao X, Jiang P, Liu B, et al
   Dual MicroRNA Simultaneous One-Step Profiling via Filler-Mediated Quantum Dot DNA Nanospheres for Bladder Cancer Screening.
   ACS Nano. 2026 Jun 13. doi: 10.1021/acsnano.6c03179.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

2. PERRET RE, Hruby M, Dehner CA, Siegmund SE, et al
   Urinary Bladder Leiomyomas: A Clinicopathological Series With Hormone Receptor, HMGA2, 2SC, and Fumarate Hydratase Status Assessment.
   Am J Surg Pathol. 2026;50:705-715.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. PENG L, Zhang Y, Zhao A, Li R, et al
   Benchmarking Large Language Models for Bladder Cancer: Comparative Knowledge Retrieval and Clinical Reasoning of DeepSeek and ChatGPT.
   Ann Surg Oncol. 2026 Jun 14. doi: 10.1245/s10434-026-19745.
   PubMed         Abstract available
   
   

   
   Anticancer Agents Med Chem

4. SHARMA A, Kumar A, Patel P, Kurmi BD, et al
   Recent Advances in Intravesical Chemotherapy: Insights into the FDA-Approved Gemcitabine-Releasing TAR-200 System for Bladder Cancer Management.
   Anticancer Agents Med Chem. 2026.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

5. SARRIO-SANZ P, Segura-Heras JV, Artes-Artes M, Belda-Ferre M, et al
   External Validation of A Decision Tree Model for Predicting Cancer-Specific Mortality After Radical Cystectomy: A Multi-Center Study in South-East Spain.
   Arch Esp Urol. 2026;79:567-575.
   PubMed         Abstract available
   
   

   
   Arkh Patol

6. MUDRAK DA, Ankudavichus VA, Mylnikov AM, Vrabie EE, et al
   [Low-grade urothelial carcinoma of the bladder with osteoclast-like differentiation as part of primary multiple malignancies. Case report and literature review].
   Arkh Patol. 2026;88:47-53.
   PubMed         Abstract available
   
   

   
   Asian J Endosc Surg

7. MORIWAKE T, Tominaga Y, Ozaki N, Matsumoto Y, et al
   Transcystostomal Bladder Tumor Resection in a Transgender Man After Phalloplasty.
   Asian J Endosc Surg. 2026;19:e70330.
   PubMed         Abstract available
   
   

   
   Biosens Bioelectron

8. XIONG Y, Xiao J, Jing L, Bian Y, et al
   Machine-learning-assisted artificial olfactory colorimetric sensor array for bladder cancer early detection from urinary volatile organic compounds.
   Biosens Bioelectron. 2026;311:118926.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. RIZZO A, Ciccimarra F, de Casio Zequi S, Bove S, et al
   Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project.
   BMC Cancer. 2026;26:756.
   PubMed         Abstract available
   
   
10. HU P, Wang C, Zeng X, Jin S, et al
    The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jun 13. doi: 10.1186/s12885-026-16326.
    PubMed         Abstract available
    
    

    
    Cancer Lett

11. SUN D, Han C, Li D, Li P, et al
    A blood-urine regulatory axis: Tumor-derived factors reprogram urine-derived stem cells via CXCL2/CXCR2/ERK signaling to drive bladder cancer stemness.
    Cancer Lett. 2026;656:218675.
    PubMed         Abstract available
    
    

    
    Cell Chem Biol

12. STUCKEY JI, Mertz JA, Wilson JE, Williamson KE, et al
    Covalent PPARgamma inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPARgamma/RXRalpha-activated urothelial carcinoma.
    Cell Chem Biol. 2026;33:837-847.
    PubMed         Abstract available
    
    

    
    Cell Death Discov

13. ZHAO S, Xu S, Cao K, Shi Y, et al
    Deficiency of LIMA1 accelerates bladder cancer progression by disrupting PINK1/Parkin-mediated mitophagy.
    Cell Death Discov. 2026 Jun 16. doi: 10.1038/s41420-026-03136.
    PubMed         Abstract available
    
    

    
    Cell Mol Biol Lett

14. LIU J, Jiang W, Wang X, Azoitei A, et al
    CRISPR and compound screens in a novel ex vivo tissue model identify DDR1 and ETA as regulators of cancer cell invasion.
    Cell Mol Biol Lett. 2026;31:84.
    PubMed         Abstract available
    
    

    
    Clin Chim Acta

15. TRABELSSI M, Lamy PJ, Daures JP, Perriard F, et al
    Xpert(R) bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.
    Clin Chim Acta. 2026 Jun 12:121169. doi: 10.1016/j.cca.2026.121169.
    PubMed         Abstract available
    
    

    
    Clin Exp Med

16. YANG Z, Ma J, Qiang Z, Xie W, et al
    ALKBH2 promotes the Warburg effect and bladder cancer progression under hypoxic conditions via the PI3K/AKT pathway.
    Clin Exp Med. 2026 Jun 15. doi: 10.1007/s10238-026-02212.
    PubMed         Abstract available
    
    

    
    Clin Transl Oncol

17. LI C, Yang Z, Zhang J, Yan X, et al
    Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer.
    Clin Transl Oncol. 2026 Jun 16. doi: 10.1007/s12094-026-04460.
    PubMed         Abstract available
    
    

    
    Discov Oncol

18. HUANG L, Li H
    Steroidogenesis is associated with bladder cancer progression via reprogramming the metabolic landscape of the tumor immune microenvironment.
    Discov Oncol. 2026 Jun 17. doi: 10.1007/s12672-026-05445.
    PubMed         Abstract available
    
    
19. HU X, Yang Z, Shi Q, Yu T, et al
    A NEK2/ZWINT-NDC80 regulatory axis drives bladder cancer progression and chemoresistance.
    Discov Oncol. 2026 Jun 13. doi: 10.1007/s12672-026-05435.
    PubMed         Abstract available
    
    

    
    Drug Resist Updat

20. ZHANG H, Li D, Su M, Zheng Z, et al
    Lactate-driven H3K18 lactylation promotes cisplatin resistance in bladder cancer via HNRNPF-Parkin mediated mitophagy.
    Drug Resist Updat. 2026;88:101435.
    PubMed         Abstract available
    
    

    
    Eur Urol

21. BASIN MF, Daneshmand S
    Cystectomy Remains Standard of Care Following Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer.
    Eur Urol. 2026 Jun 17:S0302-2838(26)02171-8. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
22. MERTENS LS, Mellema JJ, Sridhar S, van der Heijden MS, et al
    Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.
    Eur Urol. 2026 Jun 17:S0302-2838(26)02186-X. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Exp Mol Pathol

23. AHMADI P, Deyhimfar R, Haghani I, Mohammadi A, et al
    Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study.
    Exp Mol Pathol. 2026;147:105056.
    PubMed         Abstract available
    
    

    
    Fr J Urol

24. LEON P, Levi LI, Long Depaquit T, Audenet F, et al
    Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG.
    Fr J Urol. 2026;36:103105.
    PubMed         Abstract available
    
    

    
    Front Immunol

25. JIN M, Cai Z, Bu M, Liu J, et al
    From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.
    Front Immunol. 2026;17:1860957.
    PubMed         Abstract available
    
    

    
    Front Nutr

26. WU Q, Qing X, Gao W
    Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study.
    Front Nutr. 2026;13:1842495.
    PubMed         Abstract available
    
    

    
    Front Oncol

27. CITAKKUL I, Temi YB, Baydar E, Sahin E, et al
    Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications.
    Front Oncol. 2026;16:1820805.
    PubMed         Abstract available
    
    
28. LI C, Yang Z, Zhang J, Yan X, et al
    ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome.
    Front Oncol. 2026;16:1817872.
    PubMed         Abstract available
    
    
29. HE Q, Chen Y, Zhang T, Sheng W, et al
    TURBT versus RC in T1N0M0 non-urothelial bladder cancer: a population-based study.
    Front Oncol. 2026;16:1802962.
    PubMed         Abstract available
    
    

    
    Hum Immunol

30. ANDRZEJCZAK A, Krajewski W, Jaskula E, Chorbinska J, et al
    Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.
    Hum Immunol. 2026;87:111783.
    PubMed         Abstract available
    
    

    
    Immunol Res

31. WENG M, Wang X, Zhan Y, Guo Y, et al
    Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.
    Immunol Res. 2026;74:59.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

32. GU Z, Zhu H, Zhang Y, Jiang J, et al
    Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin.
    Int J Nanomedicine. 2026;21:597220.
    PubMed         Abstract available
    
    

    
    Int J Urol

33. IGARASHI A, Kinoshita T, Fujita M, Obayashi R, et al
    Intraoperative Hypotension During Photodynamic Diagnosis-Guided TURBT Under Spinal Anesthesia: A Propensity Score-Matched and Logistic Regression Analysis.
    Int J Urol. 2026;33:e70540.
    PubMed         Abstract available
    
    

    
    Intern Med

34. INOMATA H, Asatani S, Ikumi N, Uchikawa M, et al
    Malignancy-associated Multicentric Reticulohistocytosis Mimicking Dermatomyositis-like Features, with a Significant Ultrasound Finding.
    Intern Med. 2025 Nov 6. doi: 10.2169/internalmedicine.6032.
    PubMed         Abstract available
    
    

    
    J Am Vet Med Assoc

35. GORAYA DS, Cray M
    Partial cystectomy and adjuvant chemotherapy are associated with prolonged survival in dogs and cats with nontrigonal urothelial carcinoma (2010-2014).
    J Am Vet Med Assoc. 2026;264:1-7.
    PubMed         Abstract available
    
    

    
    J Endourol

36. ZHANG F, An J, Zhao L, Cao Y, et al
    Artificial Intelligence-Powered Cystoscopy Diagnostic Support System: Clinical Application of Multiarchitecture Deep Learning Models.
    J Endourol. 2026;40:925-934.
    PubMed         Abstract available
    
    

    
    J Med Internet Res

37. HE Z, Liu Y, Jiang Q, Hou F, et al
    Application Value of Radiomics-Based Machine Learning for Preoperative Risk Stratification of Bladder Cancer: Systematic Review and Meta-Analysis.
    J Med Internet Res. 2026;28:e81084.
    PubMed         Abstract available
    
    

    
    J Nanobiotechnology

38. XIAO K, Zhou B, Feng D, Yang S, et al
    Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.
    J Nanobiotechnology. 2026 Jun 13. doi: 10.1186/s12951-026-04635.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

39. SCILIPOTI P, de Angelis M, Thibault C, Slusarczyk A, et al
    Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2026 Jun 16:1-8. doi: 10.6004/jnccn.2026.7014.
    PubMed         Abstract available
    
    

    
    J Registry Manag

40. MUSCO J, Qiao B, Homich A, Kuliszewski MG, et al
    Evaluation of Cancer Cases Reported through Inter-Registry Data Exchange in New York State.
    J Registry Manag. 2026;53:15-21.
    PubMed         Abstract available
    
    

    
    Mil Med Res

41. HE YB, Hu J, Liu Z, Xiao ZC, et al
    Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort study.
    Mil Med Res. 2026;13:100001.
    PubMed         Abstract available
    
    

    
    Mod Pathol

42. ERIKSSON P, Cotillas EA, Mattsson CA, Zadoroznyj A, et al
    Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.
    Mod Pathol. 2026;39:100997.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

43. YI LIN LEE MC, Camargo JA, Caetano Vilas Boas G, Silva KS, et al
    CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.
    Mol Biol Rep. 2026;53:973.
    PubMed         Abstract available
    
    

    
    Mol Genet Genomics

44. SONG W, Han G, Li Z, Hu J, et al
    Single-cell transcriptomics identifies key immune-suppressive cells and their driver genes in the bladder cancer microenvironment with prognostic implications.
    Mol Genet Genomics. 2026;301:142.
    PubMed         Abstract available
    
    

    
    Mol Oncol

45. KOTOLLOSHI R, Berndt-Paetz M, Lerner E, Najjar G, et al
    ZW4864-mediated inhibition of the beta-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer.
    Mol Oncol. 2026 Jun 18. doi: 10.1002/1878-0261.70292.
    PubMed         Abstract available
    
    

    
    N Engl J Med

46. VULSTEKE C, Ullen A
    Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.
    N Engl J Med. 2026;394:2383.
    PubMed        
    
    
47. COLD KM, Vasquez JL
    Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
    N Engl J Med. 2026;394:2382-2383.
    PubMed        
    
    

    
    Nat Cell Biol

48. WANG Z
    Spatial profiling in bladder cancer.
    Nat Cell Biol. 2026;28:1089.
    PubMed        
    
    

    
    Photodiagnosis Photodyn Ther

49. SAGAWA T, Ishida T, Jobu K, Sakoda R, et al
    Risk factors for intraoperative hypotension associated with the use of oral 5-aminolevulinic acid as a photodynamic diagnostic agent in transurethral resection of bladder tumors: A meta-analysis.
    Photodiagnosis Photodyn Ther. 2026;59:105403.
    PubMed         Abstract available
    
    

    
    Rev Assoc Med Bras (1992)

50. BALCI S, Tanriverdi R, Nebioglu A, Yildirim DD, et al
    Elevated serum Raftlin levels in non-muscle invasive bladder cancer: diagnostic implications and rs690037 genotype analysis.
    Rev Assoc Med Bras (1992). 2026;72:e20251628.
    PubMed         Abstract available
    
    

    
    Sci Rep

51. CELLA L, Fasulo V, Uleri A, Piccolini A, et al
    Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.
    Sci Rep. 2026 Jun 14. doi: 10.1038/s41598-026-57805.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

52. REICHARD C, Trainer A, Grant K, Asgarisabet P, et al
    Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2026;15:180.
    PubMed         Abstract available
    
    
53. LI Y, Liu Y, Xi J, Li X, et al
    Super-selective bladder arterial chemotherapy for muscle invasive bladder cancer.
    Transl Androl Urol. 2026;15:172.
    PubMed         Abstract available
    
    
54. KOGUCHI D, Shiba I, Shiono Y, Matsumoto K, et al
    Diagnostic potential of urinary PENK methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study.
    Transl Androl Urol. 2026;15:145.
    PubMed        
    
    
55. CHEN Y, Zheng J, Li D, Wu Q, et al
    Association between prognostic nutritional index (PNI)/Controlling Nutritional Status (CONUT) score and prognosis in patients with bladder cancer: a systematic review and meta-analysis.
    Transl Androl Urol. 2026;15:167.
    PubMed         Abstract available
    
    
56. WANG T, Wei B
    Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease-a retrospective cohort study.
    Transl Androl Urol. 2026;15:153.
    PubMed         Abstract available
    
    

    
    Urol Oncol

57. YORULMAZ EM, Akin Y, Donmez K, Gorgel SN, et al
    Predictive value of the HAS-BLED score in the course of radical cystectomy: A pilot study.
    Urol Oncol. 2026;44:297-306.
    PubMed         Abstract available
    
    
58. JOKELAINEN O, Ruotsalainen L, Ikonen E, Nykopp TK, et al
    The Paris System for reporting urinary cytology in the follow-up of non-muscle-invasive bladder cancer.
    Urol Oncol. 2026;44:173-181.
    PubMed         Abstract available
    
    
59. ABDELSHAFI A, Mohamed T, Mohamed H, Mohammed YA, et al
    Hand-sewn versus stapled ileo-ileal anastomosis following radical cystectomy: A systematic review and meta-analysis.
    Urol Oncol. 2026;44:215-224.
    PubMed         Abstract available
    
    
60. MARCHETTI KA, Asees A, Bokil AP, Medich M, et al
    Survivor-identified barriers and facilitators to acute phase recovery following radical cystectomy.
    Urol Oncol. 2026;44:234-242.
    PubMed         Abstract available
    
    
61. LEI D, Wu JH, Zeng XH, Xu R, et al
    Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis.
    Urol Oncol. 2026;44:182-194.
    PubMed         Abstract available
    
    

    
    Urology

62. MALSHY K, Lim K, Jia Y, Guo W, et al
    Utilization and Costs Among Bladder Cancer, Other Cancer, and Non-Cancer Populations in the United States.
    Urology. 2026 Jun 14:S0090-4295(26)00373-0. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

    
    Virchows Arch

63. KOBAYASHI G, Sekino Y, Hayashi T, Nakahara H, et al
    Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance.
    Virchows Arch. 2026;488:1227-1242.
    PubMed         Abstract available
    
    

    
    World J Urol

64. WANG C, He S, Zhang B, Zhang S, et al
    Development and multicohort validation of an interpretable postoperative model for intravesical recurrence after radical nephroureterectomy in upper tract urothelial carcinoma.
    World J Urol. 2026;44:425.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum